Replimune Group, Inc. (REPL) plunged 44.74 percent to $3.15 on Thursday, down $2.55, after the company said it had completed a Type A meeting with the U.S. Food and Drug Administration regarding the complete response letter tied to its Biologics License Application for RP1 in combination with nivolumab for advanced melanoma. The stock opened at $4.12 and traded between $3.15 and $4.44, compared with a prior close of $5.71 on the Nasdaq. Trading volume surged to 15.9 million shares, well above the average of 9.3 million. Replimune now trades within a 52-week range of $2.68 to $17.00.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.